Stephen Wright Email & Phone Number

Switzerland 🇨🇭 , Ch

Stepped into a new role at Roche/GNE in response to COVID-19 and evolving data, revealing globally approved biologic therapy (Actemra) could help patients with severe COVID-19 pneumonia. Took the lead of an Executive level team to help steer a cross-functional team of ~500 people globally to progress novel studies through approval and market delivery in record time. Recipient of 2 Roche Rethink Development Awards. Scientific + Strategic Leadership: Outpaced competitors, breaking all previous records for study startup, conduct, and analysis of 3 global phase 3 studies of Actemra and earned emergency use authorization (EUA) for COVID-19 and EMA approval.- Steered delivery of first submission to WHO (2021) for a Roche medicine product qualification and earned placement in WHO guidelines for viable treatment of COVID-19.- Partnered with WHO, devising a plan for Actemra availability in developing countries.  Build Relationships with Key Scientific Experts: Engaged with and supported >15 globally initiated studies, including the largest clinical study of severe COVID-19 led by the UK (The RECOVERY study).  Champion Solutions to Complex Challenges: Provided leadership necessary to nearly triple Actemra product supply, positioning company, and capability to treat >1M patients experiencing severe COVID-19 with 60% of those affected from developing countries. - Ensured continuity of product + equitable distribution, managing central allocation of supply and meeting unprecedented demand.- Minimized country-level stock-outs, collaborating with multiple NGOs and Governmental organizations on sustainable strategies to enhance supply and meet demand.

Switzerland 🇨🇭 , Ch

Strengthened global product strategy, leading, aligning, and mobilizing teams focused on immunology, ophthalmology, and infectious diseases to maximize sales potential, minimize time-to-market, and deliver financial returns. Led teams accountable for CHF 1.5b brand. Propelled the Frontiers of Healthcare: Served as a liaison, reporting to SVP of Global Product Strategy, supporting the development of AntiCD20 franchise in immunology and BTKi molecule (Fenebrutinib).- Provided executive direction, holding accountability for setting strategic context, clinical development, medical + brand planning, technical and product supply, signal seeking, budgetary oversight, and resource allocation for molecules Fenebrutinib, Rituximab, and Obinutuzumab in immunology.

Switzerland 🇨🇭 , Ch

Steered global product development, immunology, ophthalmology, and infectious diseases as clinical head of late-stage development for Actemra in a direct report relationship to the SVP of Clinical Development. Additional accountabilities included serving as Development Review Committee Chair Delegate (responsible for all decision related to development activities) and as final signature authority for Clinical Development and Regulatory submission documents.

Switzerland 🇨🇭 , Ch

Served as interim lifecycle leader, global product development, immunology, and infectious diseases. Headed cross-functional strategic teams. Set goals and initiated plans for annual lifecycles and maintained international partnerships. Successfully attained funding for phase III program in Systemic Sclerosis.

Switzerland 🇨🇭 , Ch

Continued to make a positive impact, leading to assignment as Global Development Team Leader for Actemra. Synchronized the efforts of global development teams in South San Francisco, New York, Welwyn, Basel, and Beijing. Implemented best practices to achieve program milestones in adult RA, pediatric arthritis, vasculitis, other rheumatic diseases, new device delivery programs, ophthalmology diseases, and oncology.  Key participant in the company’s Leadership Executive Training Program and Lifecycle Team in Action Course. Held strategic oversight of the Development Review Committee, which was responsible for all decisions related to development activities: health authority interactions, clinical development approvals/execution, resource allocation, cost, budget, and timeline planning.

Switzerland 🇨🇭 , Ch

Promoted to high-visibility and accountability leadership role overseeing global clinical program, Actemra subcutaneous (2 phase 3 studies and SC device development program). Provided clinical input, defining and implementing confirmatory development strategy across the entire life cycle for Actemra. Demonstrated influential and expert-level communication skills as a clinical representative for local and global advisory boards. Formed KOL relationships with target-market healthcare professionals and experts. Global exposure included leading SC clinical development program in China; co-development experience with Chugai Pharmaceuticals based in Japan.  Paired efforts with diverse leaders, interacting with team members in commercial, medical affairs, regulatory, clinical pharmacology, technical device, safety, operational, and biometrics.  Led a team of 8 scientists/physicians spread across San Francisco and the UK; served as a mentor for clinical group based in China.

Switzerland 🇨🇭 , Ch

Switzerland 🇨🇭 , Ch

Began career at Roche as a lead clinical scientist with oversite of global pediatric clinical development program (Actemra IV Program). Mentored and directed scientists based in New Jersey and the UK. Served as clinical lead for FDA, EMA, and ROW post submissions and regulatory interactions, which resulted in the first global approval of IV Actemra in 2011.

Provided care to patients in the specialty of general rheumatology. Excelled at diagnosing and managing the care of patients with a wide range of conditions, including inflammatory autoimmune diseases. Prioritized the care of patients undergoing biologic therapies within this large academic teaching hospital known for its dedication to excellence in patient care.

Interim Consulting Rheumatologist/Senior Lecturer at Queen’s University Belfast and Musgrave Park Hospital, Northern Ireland

Pediatric Rheumatology Training and Advanced Musculoskeletal Ultrasound Training, Royal Victoria Hospital, Belfast City Hospital, and Musgrave Park Hospital, Northern Ireland Deanery Training Rotation

Belfast, Antrim, Gb

Strong research-based foundation in the department of therapeutics and pharmacology (Queen’s University Belfast, Northern Ireland). Awarded the first-ever "Welcome Trust Clinical Research Fellowship in Northern Ireland" and benefitted greatly from a 2-year research program: synthesizing the relationship between endothelial dysfunction, free radical production, and accelerated atherosclerosis in patients with systemic lupus erythematosus the potential effect of omega-3-fatty acids.

Doctor Of Medicine Md, Medicine

Mrcp(Uk), Medicine

Bachelor Of Medicine, Mb(Hons) Bch Bao, Medicine